Iron oxide magnetic particles
US-2024058449-A1 · Feb 22, 2024 · US
US9320719B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9320719-B2 |
| Application number | US-201414294636-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 3, 2014 |
| Priority date | Mar 15, 2011 |
| Publication date | Apr 26, 2016 |
| Grant date | Apr 26, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides nanoparticles including a metallic core having a length along each axis of from 1 to 100 nanometers and a coating disposed on at least part of the surface of the metallic core, wherein the coating comprises polydopamine, along with methods for making and using such nanoparticles. The metallic core may be gold, silver or iron oxide and the polydopamine coating may have other substances bound to it, such as silver, targeting ligands or antibodies, or other therapeutic or imaging contrast agents. The disclosed nanoparticles can be targeted to cells for treating cancer or bacterial infections, and for use in diagnostic imaging.
Opening claim text (preview).
We claim: 1. A method for treating cancer comprising administering to a patient having cancer cells one or more nanoparticles comprising: (a) a metallic core consisting essentially of gold and having a length along each axis of from 1 to 100 nanometers; (b) a coating comprising polydopamine disposed on at least part of the surface of the metallic core; and (c) one or more cetuximab anti-cancer cell surface receptor antibodies; whereby the one or more nanoparticles target the cancer cells and the cancer is effectively treated, and wherein the cancer is selected from the group consisting of metastatic colorectal cancer, head and neck cancer, and epidermal growth factor receptor (EGFR)-expressing breast cancer. 2. The method of claim 1 , wherein the one or more nanoparticles further comprise an additional anti-cancer agent bound to the coating. 3. The method of claim 2 , wherein the anti-cancer agent is a proteasome inhibitor. 4. The method of claim 1 , further comprising the step of exposing the nanoparticles to light. 5. A method for treating cancer, the method comprising: administering to a patient having cancer cells one or more nanoparticles comprising: (a) a metallic core consisting essentially of gold and having a length along each axis of from 1 to 100 nanometers; (b) a coating comprising polydopamine disposed on at least part of the surface of the metallic core; and (c) one or more cetuximab anti-cancer cell surface receptor antibodies; and exposing the nanoparticles to light, whereby the one or more nanoparticles target the cancer cells and the cancer is effectively treated, and wherein the cancer is selected from the group consisting of metastatic colorectal cancer, head and neck cancer, and epidermal growth factor receptor (EGFR)-expressing breast cancer.
Photodynamic therapy, i.e. excitation of an agent · CPC title
Iron; Compounds thereof · CPC title
Antineoplastic agents · CPC title
spatially resolved investigating of object in scattering medium (in vivo A61B) · CPC title
Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.